Literature DB >> 7498253

Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures.

A G Estevez1, J M Stutzmann, L Barbeito.   

Abstract

Excitatory amino acid-mediated neurotoxicity was investigated in motoneuron-enriched cultures from fetal rats at 12-14 days of gestation. The cultures were mainly composed of differentiated motoneurons identified by choline acetyl transferase and calcitonin gene-related peptide (CGRP) immunoreactivity. Addition of glutamate (600 microM) to the conditioned medium induced no acute neuronal swelling. However, it was followed by a widespread neuronal degeneration over the next 24 h, accounting for 77% of the total cell number. Glutamate toxicity was dose dependent, with an EC50 around 300 microM. Treatment for 24 h with the agonists, N-methyl-D-aspartate (NMDA, 100 microM), kainate (500 microM) or RS-alpha-amino-3-hydroxy-5-methyl-4-isoxalopropionate (AMPA, 10 microM), also induced a significant cell loss. Riluzole (2 amino 6-trifluoromethoxybenzothiazole), a compound known to interfere with glutamatergic transmission pre- and postsynaptically, significantly reduced glutamate and NMDA neurotoxicity in a dose-dependent manner. These results suggest that a prolonged activation of one or more subtypes of ionotropic excitatory amino acid receptors can lead to motoneuron degeneration in vitro, and provide direct experimental evidence supporting the neuroprotective effect of riluzole in cultured motoneurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498253     DOI: 10.1016/0014-2999(95)00186-o

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Increased survival and reinnervation of cervical motoneurons by riluzole after avulsion of the C7 ventral root.

Authors:  Sándor Pintér; Balázs Gloviczki; András Szabó; Gábor Márton; Antal Nógrádi
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

2.  Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.

Authors:  Alice Y C Liu; Rohan Mathur; Newton Mei; Christopher G Langhammer; Bruce Babiarz; Bonnie L Firestein
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

3.  Effect of glutamate on dendritic growth in embryonic rat motoneurons.

Authors:  F Metzger; S Wiese; M Sendtner
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

Review 4.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

5.  Effects of riluzole on electrically evoked neurotransmitter release.

Authors:  T Jehle; J Bauer; E Blauth; A Hummel; M Darstein; T M Freiman; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 6.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 7.  Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis.

Authors:  P J Shaw; C J Eggett
Journal:  J Neurol       Date:  2000-03       Impact factor: 4.849

8.  Chronic inhibitory effect of riluzole on trophic factor production.

Authors:  Cassandra N Dennys; JeNay Armstrong; Mark Levy; Youn Jung Byun; Kristina R Ramdial; Marga Bott; Fabian H Rossi; Cristina Fernández-Valle; Maria Clara Franco; Alvaro G Estevez
Journal:  Exp Neurol       Date:  2015-06-10       Impact factor: 5.330

Review 9.  Stronger is not always better: could a bodybuilding dietary supplement lead to ALS?

Authors:  Marin Manuel; C J Heckman
Journal:  Exp Neurol       Date:  2010-12-15       Impact factor: 5.330

10.  Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.

Authors:  H J M van Kan; G J Groeneveld; S Kalmijn; M Spieksma; L H van den Berg; H J Guchelaar
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.